China's Sichuan Kelun-Biotech swings to profit in H1 on new product approvals

Sichuan Kelun-Biotech Biopharmaceutical

17/08/2026 12:26

Overview
China biopharma firm's interim revenue rose 2.9% yr/yr to RMB978.3 mln
Company swung to net profit of RMB388 mln from loss a year earlier
Results driven by new product approvals and expanded oncology indications

Outlook
Company did not provide specific financial or operational guidance

Result Drivers
NEW PRODUCT APPROVALS - Co cited recent marketing authorizations for sac-TMT and trastuzumab botidotin as drivers of performance
EXPANDED INDICATIONS - Co said expanded indications for sac-TMT in breast and lung cancers contributed to results
POSITIVE CLINICAL DATA - Co highlighted positive Phase 3 trial results and data presentations for sac-TMT and other assets

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 978.30 mln
 
H1 Net Income Attributable
 
RMB 388 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is HK$560.00, about 7.2% above its August 17 closing price of HK$522.50
The stock recently traded at 335 times the next 12-month earnings vs. a P/E of 953 three months ago

Reuters Recommended Reads
Aug 17 - Sandoz to license three biosimilar drugs from Shanghai Henlius Biotech
Aug 14 - Jilin Changlong Bio-pharmacy interim profit rises on lower costs
Aug 14 - Cancer diagnostics firm Precipio's Q2 revenue rises, adjusted EBITDA turns positive

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-17/f59497f2-cd79-46f0-a331-af92472e902b.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)